Cinctive Capital Management LP Cuts Stock Position in Vera Therapeutics, Inc. $VERA

Cinctive Capital Management LP cut its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 40.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 96,573 shares of the company’s stock after selling 65,510 shares during the period. Cinctive Capital Management LP’s holdings in Vera Therapeutics were worth $2,806,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in Vera Therapeutics in the 2nd quarter worth approximately $51,000. Virtus Investment Advisers LLC grew its position in Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after acquiring an additional 2,757 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Vera Therapeutics by 414.2% during the third quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock worth $152,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Vera Therapeutics by 13.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock worth $124,000 after acquiring an additional 615 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Trading Down 2.9%

NASDAQ:VERA opened at $39.96 on Monday. The company has a fifty day moving average of $43.81 and a 200 day moving average of $36.96. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $2.80 billion, a P/E ratio of -8.58 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period last year, the company earned ($0.72) EPS. On average, research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VERA. Pivotal Research set a $73.00 price objective on shares of Vera Therapeutics in a research note on Friday, December 5th. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. The Goldman Sachs Group raised their price objective on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Evercore lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $81.45.

Insider Activity at Vera Therapeutics

In related news, CFO Sean Grant sold 4,949 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the sale, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William D. Turner sold 2,187 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $91,810.26. Following the transaction, the insider owned 45,313 shares in the company, valued at approximately $1,902,239.74. This represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 33,490 shares of company stock valued at $1,405,910 in the last quarter. 16.30% of the stock is currently owned by company insiders.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.